Hims & Hers Launches $300M Convertible Notes Offering for Expansion and AI Investments

What happened

Hims & Hers announced a $300 million convertible senior notes offering due 2032, with proceeds earmarked for international expansion and AI-driven platform investments. The company, already navigating a strategic pivot from compounded to branded GLP-1 weight-loss drugs, reported Q1 2026 gross margin compression to 65% and a $92 million net loss, while facing DOJ referral and FTC investigation risks. The offering comes despite $750.9 million in liquidity as of March 31, 2026, suggesting additional capital is needed to fund the pending $1.15 billion Eucalyptus acquisition and support the pivot. Convertible notes will likely dilute existing shareholders upon conversion, adding further pressure on a stock already down over 50% from a year ago. Management is effectively raising debt to buy time while the market waits for evidence that branded GLP-1 economics can stabilize margins and sustain growth.

Implication

The convertible offering introduces dilution risk and signals that cash flow alone may not cover the pivot costs and acquisition ambitions. In the near term, the stock will likely trade down on the dilution overhang. Over the next 6–12 months, the key tests are Q2 2026 revenue and EBITDA versus guidance ($680M–$700M and $35M–$55M), gross margin stabilization, and branded GLP-1 momentum. If the company shows it can scale branded volume without further margin decay and without new regulatory enforcement, the offering could be seen as a growth enabler. However, given the existing regulatory tail risks (DOJ, FTC, Novo patent refiling), the margin of safety remains thin. Wait for concrete improvements in reported margins and subscriber economics before considering a position.

Thesis delta

The convertible notes offering adds a new layer of shareholder dilution and financial leverage, raising the bar for the stock to re-rate. Previously, the investment thesis hinged on the success of the branded GLP-1 pivot without major regulatory blowback; now, the need for external capital implies management sees the pivot as capital-intensive and perhaps riskier than earlier assumed. The offering reduces the likelihood of near-term upside absent a clear catalyst (e.g., DOJ closure, margin re-expansion) and increases the probability of downside if Q2 results disappoint or enforcement escalates.